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Summary 
This study investigates the molecular mechanisms underlying the induction of and protection 
from T cell activation-associated hepatic injury. When BALB/c mice were given a single intravenous 
injection of concanavalin A (Con A) (>10.3 rag/mouse), they developed acute hepatic injury as 
assessed by a striking increase in plasma transaminase levels within 24 h. Histopathologically, 
only the liver was injured while moderate infiltration  of T  cells and polymorphonuclear cells 
occurred in the portal areas and around the central veins. The induction of hepatic injury was 
dependent on the existence as well as the activation of T cells, as untreated BALB/c nu/nu mice 
or BALB/c mice pretreated  with a T  cell-specific immunosuppressive  drug, FK506,  failed to 
develop disease. Significant increases in the levels of various cytokines in the plasma were detected 
before an increase in plasma transaminase levels. Within 1 h after Con A injection, tumor necrosis 
factor (TNF) levels  peaked, this being followed by production of two other inflammatory cytokines, 
interleukin 6 (IL-6) and IL-1. Passive immunization with anti-TNF but not with anti-IL-1 or 
anti-IL-6 antibody, conferred significant levels of protection. Moreover, administration of rlL-6 
before Con A injection resulted in an IL-6 dose-dependent  protection. A single administration 
of a given dose of rlL-6 completely inhibited the release of transaminases, whereas the same 
regimen induced only 40-50% inhibition of TNF production. More than 80% inhibition of 
TNF production required four consecutive rlL-6 injections. These results indicate that: (a) TNFs 
are critical cytokines for inducing T  cell activation-associated  (Con A-induced) hepatitis;  (b) 
the induction of hepatitis is almost completely controlled by rlL-6; and (c) rlL-6 exerts its protective 
effect through multiple mechanisms  including the reduction of TNF production. 
H 
'epatitis represents a worldwide health problem in humans 
￿9  for which pharmacological  treatments have yet to be 
discovered. Development of new drugs, however, depends pri- 
marily on the availability of animal models relevant to human 
hepatitis or hepatocellular damage. For instance, active chronic 
hepatitis leading to liver cirrhosis is a disease state in which 
liver parenchymal  cells are progressively destroyed by acti- 
vated T cells (1). The commonly used model of liver injury 
induced by chemicals (2), however, does not accurately rep- 
resent  the clinical situation. 
It has been reported that the administration of endotoxin 
from gram negative bacteria (LPS) to rodents leads to endo- 
toxic shock (3, 4). The injection of LPS at subtoxic amounts 
into D-galactosamine-treated  animals results in hepatic in- 
jury under conditions in which other organs are not affected 
by LPS (5, 6). Since the hepatic lesions induced in this model 
resemble those of human viral hepatitis  (7), this has been 
regarded as an appropriate human hepatitis model. Although 
this type of hepatitis is likely to be based on the production 
of endogenous mediators and their biological actions (8-10), 
pretreatment with D-galactosamine  is an absolute requirement, 
and this substance is known to be a specific hepatotoxic agent 
(11). In contrast, another hepatitis model was recently devel- 
oped in which liver-specific inflammatory lesion is induced 
by injection of Con A without pretreatment with D-galactoo 
samine (12). Con A-induced routine hepatitis has provided 
a novel model in that hepatitis is induced as a consequence 
of T cell activation. However, molecular mechanisms of en- 
dogenous mediators underlying the Con A-induced hepa- 
titis have not been analyzed. 
The present study was undertaken to investigate the roles 
of various cytokines in the induction of and protection from 
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A-induced hepatitis is T cell activation dependent and that 
the induction of hepatitis is associated with the production 
of various cytokines. TNF is the first cytokine produced after 
Con A injection, and is the most critical in inducing hepa- 
titis as anti-TNF antibody confers protection against disease. 
Hepatitis was also prevented by administration of rlL-6. Im- 
portantly, rlL-6 was more effective in the prevention of trans- 
aminase release than in the inhibition of cytokine (TNF) 
production, implying that IL-6 functions to enhance host 
resistance as well. Thus, these results indicate a role for var- 
ious cytokines in the induction  vs regulation  of T  cell-de- 
pendent hepatic injury. 
Materials and Methods 
Mice.  Female BALB/c  (+/+)  mice were purchased from the 
Shizuoka Experimental Animal Center (Shizuoka, Japan), and were 
used at 7-10 wk of age. BALB/c (nu/nu) mice were obtained from 
Charles River Japan Inc. (Kanagawa, Japan). 
Reagents.  Con A was purchased from Vector Laboratories, Inc. 
(Burlingame, CA). FKS06 was from our company (Fujisawa Phar- 
maceutical Co. Ltd.). Recombinant human Ib6 was expressed on 
CHO cells and purified in our company. Anti-TNF mAb capable 
of neutralizing TNF-ot and TNF-/3, and anti-IL-l~ antiserum were 
obtained from Genzyme Corp. (Cambridge, MA) and Advanced 
Magnetics,  Inc.  (Cambridge,  MA),  respectively.  Hybridoma- 
producing antimurine II-,6 mAb (6B4)  (13) was a generous gift 
from Dr. J. Van Snick (Ludwig Cancer Institute for Cancer Re- 
search,  Brussels,  Belgium).  Purified mAb from ascitic  fluid  was 
used. The following reagents were purchased to perform immuno- 
histochemical examination: purified rat anti-mouse CD4 and CD8 
mAb (Pharmingen,  San Diego, CA);  normal rat IgG as control 
(Biomeda, Foster City, CA); peroxidase Affmi Pure mouse anti-rat 
IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA); 
and 3-amino-9-ethylcarbazole (AEC) (Aldrich Chemical Co., Mil- 
waukee,  WI). 
Treatment of Mice.  Con A was dissolved in pyrogen-free saline 
and administered to mice via the tail vein. rlL-6 was diluted with 
pyrogen-free saline and administered to mice subcutaneously.  FK506 
was administered to mice orally in a dose of 32 mg/kg. Anti-TNF, 
anti-IL-1, and anti-Ib6 antibodies were injected into mice intrave- 
nously. 
AssayforPlasma TransaminaseActivities.  Plasma from individual 
mice was obtained at various time intervals after Con A injection. 
Plasma transaminase activity was measured by the standard photo- 
metric method (14) using a bichromatic analyzer (model 100; Ab- 
bott Laboratories, North Chicago,  IL). 
Assays for Cytokine Levels in Plasma.  TNF, IL-1, IL2 (Genzyme 
Corp.), and Ib6 (Endogen, Inc., Boston, MA) amounts in plasma 
were assayed by ELISA kits. The assays were performed exactly as 
described by the manufacturer.  Each  sample was determined in 
duplicate. 
Histological Examination.  Various organs including the liver from 
individual mice were fixed in 10% formalin, embedded in paraflqn, 
sectioned, and stained with hematoxylin and eosin for histological 
examination. 
Staining Procedure of lmrnunohistochemical Examination.  Cryostat 
sections (5 #m) were cut,  air-dried at room temperature for 2 h, 
fared in acetone for 10 min, and air dried. Before staining, the sec- 
tions were washed in PBS.  The tissues were overlayed  with the 
appropriately diluted nonlabeled primary antibody, and incubated 
for 1 h in a humidified chamber at room temperature. The sections 
were then washed in three changes of PBS and dipped in methyl 
alcohol with 0.3%  hydrogen peroxide (10 min) for blocking of 
endogenous peroxidase activity. The sections were then incubated 
with peroxidase-labeled mouse anti-rat IgG for 1 h. After another 
wash in PBS, the sections were stained with AEC for several minutes 
to develop the color and washed in water. The sections were coun- 
terstained with hematoxylin for 30 s. 20 sections  were prepared 
from each liver. Sequential parallel sections exhibiting a typical cel- 
lular infiltration  are presented in each figure. 
Statistical  Analysis.  Results  are  expressed  as  mean  _+  SE. 
Statistical analysis  was performed using Student's t test. 
Results 
Induction  of Acute  Liver  Injury  After  Con  A  Administra- 
tion.  BALB/c mice were intravenously injected with different 
doses of Con A, and transaminase activities were measured 
in plasma from mice at various intervals after Con A  injec- 
tion (Table 1 and Fig. 1). The results demonstrate that a single 
Table  1.  Dose.dependent  Increase in Plasma Transaminase Activities 
after Con A  Injection 
Plasma transaminase level  NO.  of 
Dose of Con  A  mice  AST  ALT 
(rag~mouse)  U/liter 
0*  5  119_+  12  47_+  5 
0.1  5  167  _+  16  129  +  16 
0.3  5  5,458  _+  1,670  3,516  +_.  1,170 
0.5  5  7,564  +_  2,414  4,438  _+  1,488 
* BALB/c mice were injected intravenously with indicated doses of Con 
A. Plasma from these mice was obtained 24 h after Con A injection. 
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Figure 1.  Time course of increase in plasma transaminase levels after 
Con A injection. Five BALB/c mice were injected intravenously with 0.3 
mg/mouse Con A. Plasma from individual mice was obtained at various 
hours after Con A injection. Data points represent the mean  +_ SE of 
transaminase activity (U/I)  in plasma obtained at each time point. 
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proximately equal to 15 mg/kg) elicits a striking increase in 
plasma transaminase  levels. Such an increase was detectable 
as early as 8 h after Con A injection,  and after reaching the 
peak levels at around 24 h,  the levels decreased within 48 h 
after the injection. 
Histological and Immunohistochemical  Examination.  Various 
organs  including  the liver,  spleen,  kidney,  lung,  and heart 
were removed various hours after Con A injection. Light mi- 
croscopic examination revealed that only the liver was severely 
affected. No significant  changes were observed in other organs 
(data not  shown). 
Fig. 2 shows the time course of hepatic injury.  8 h  after 
Con A injection,  slight degenerative changes in hepatocytes 
were observed, but necrosis and cellular infiltration were not 
detected (Fig. 2, A-C).  After 24 h, moderate infiltration of 
mononuclear and polymorphonuclear cells were seen in the 
portal area within the Glisson's capsules (Fig. 2 F) and around 
the central  vein.  Spotty, focal,  and massive necroses devel- 
oped and hepatocytes between these necrotic areas exhibited 
vacuolar and vesicular cytoplasmic changes  (Fig.  2, D  and 
E).  These changes continued  to exist in  the  sections 48 h 
after Con A injection (Fig. 2, G, H, and/), by which time 
the progress of hepatic injury had ceased. In addition, infiltrated 
Figure  2.  Light  micrographs of the liver from mice various hours after Con A injection. BALB/c  mice were injected with 0.3 mg/mouse Con 
A. The livers were removed 8 (A-C), 24 (D-F), and 48 h (G-/) after Con A injection. (Hematoxylin and eosin staining for A, D, and G:  x25; 
for B, C, E, F, H, and t:  x 50). 
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the necrotic areas (Fig. 2,  G  and/4). 
To determine whether mononuclear cells infiltrating  the 
liver represent T cells, we performed immunohistochemical 
analyses using cryostat sections of the liver 24 h after Con 
A injection.  Fig. 3 (top for the portal area and bottom for the 
central vein area) shows that a large number of  cells are stained 
with anti-CD4 mAb and a relatively small number of cells 
exhibit the CD8 phenotype. The infiltration of either CD4 § 
or CD8 +  T  cells was  not  detected in  the sections  from 
normal mice (data not shown). Taken collectively, hepatic 
injury is summarized to consist of (a) the degeneration of 
parenchymal cells and the existence of necrotic areas, and (b) 
moderate-to-severe infiltration of  polymorphonuclear as well 
as mononuclear cells, including a large number of CD4 + T 
cells. 
Con A-induced Hetmtitis Is Dependent on T Cell Activation.  It 
is known that Con A is a lectin that induces generalized T 
cell activation. Therefore, we next asked whether the induc- 
tion of hepatitis induced by Con A administration is based 
on T cell activation. When athymic nude mice (BALB/c  nu/nu) 
were injected with Con A (0.3 rag/mouse), they did not de- 
velop severe hepatic  injury (Fig. 4 A). The results in Fig. 
4 B demonstrate that the administration of  FK506 before Con 
A injection is capable of  inhibiting T cell activation, resulting 
in protection of euthymic BALB/c mice that would other- 
wise suffer from severe hepatitis. These results indicate that 
the development of Con A-induced hepatitis requires both 
the presence and activation  of T  cells. 
Elevation of  Plasma Cytokine Levels in Mice After Con A  In- 
jection.  To investigate which types of  endogenous mediators 
are produced to induce liver injury after Con A injection, 
we examined  the plasma  levels of various cytokines/lym- 
phokines. IL-2 is, in general, the most representative oflym- 
phokines produced by antigen- or lectin (Con A)-activated 
T  cells. In this model, a significant increase in the plasma 
level of this lymphokine was observed at early time points 
after Con A injection with the peak response around 2-4 h 
after the injection (Fig. 5 A). We also examined the plasma 
levels of inflammatory cytokines including TNFs, IL-1, and 
IL-6. The results are summarized in Fig. 5, B-D. A striking 
increase in the levels of all three cytokines was observed ear- 
lier than an increase in plasma transaminase levels. Notably, 
TNF levels were elevated as early as 1 h after Con A injec- 
tion. Fig. 5, B-D also illustrates that the strikingly elevated 
levels of these three cytokines decreased sharply although the 
levels after 24 h remained slightly increased compared with 
those from normal untreated animals. 
Anti-TNF Antibody Prevents Con A-induced Hepatitis.  To 
investigate how cytokines induced in vivo by Con A con- 
tribute to the development of acute liver injury,  we exam- 
ined the protective effect of passive immunization with an- 
ticytokine antibodies. The results in Table 2 demonstrate that 
passive immunization with anti-TNF antibody conferred pro- 
tection, whereas pretreatment with anti-IL-1 or anti-IL-6 an- 
tibody failed to prevent disease development. These results 
indicate that TNF which is produced earliest after Con A 
injection plays a critical role in the development of Con A-in- 
duced hepatitis. 
rlL-6 Confers  Protection  of  Con A-induced Hepatitis.  As men- 
tioned previously, the production of TNF was followed by 
the production of other cytokines, IL-6 and IL-1. We there- 
Figure 3.  Staining of hepatitis lesion with various mAb. Frozen sections of the liver harvested 24 h after Con A injection were stained with either 
normal control rat IgG (/1 and B), rat anti-mouse CD4 (C and D), or rat anti-mouse CD8 mAb (E and F), followed by peroxidase-labeled mouse 
anti-rat IgG and AEC. Original magnification  of 50). 
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Figure  5.  Release of various  lymphokines/cytokines  into the plasma 
after Con A injection.  Plasma from individual  mice was obtained  at var- 
ious hours after Con A (0.3 mg/mouse) injection. Data points represent 
the mean  _+  SE for five animals killed at each time point. 
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Figure 4.  Dependence  of Con A-induced hepatitis  on T  cell activa- 
tion. (A) Five BALB/c and five BALB/c nu/nu mice were injected with 
0.3 mg/mouse of Con A. (B) Normal BALB/c mice were injected with 
0.3 mg/mouse of Con A. These mice (five mice per group) were given 
a single injection of 32 mg/kg FK506 at various times (indicated). Plasma 
were obtained  24 h after  Con A injection. 
fore investigated whether these secondary cytokines augment 
the role of TNF in inducing hepatitis or function to stimu- 
late host defense. Various doses of rlL-6 were administered 
to mice 6 h before Con A injection, and plasma transaminase 
(ALT)  1 levels were determined 24 h  after Con A injection. 
The results of Fig. 6 illustrate that pretreatment of mice with 
rlL-6 produces IL-6 dose-dependent protection of liver in- 
jury. Additional experiments were performed to determine 
whether the protective effect of rlL-6 is related to the time 
of administration of this cytokine, rlL-6 was administered 
at a given dose (20/~g/mouse) at various times before or after 
Con A injection (Fig.  7).  The rlL-6 administration before 
Con A injection (24-3 h) conferred almost complete protec- 
tion, whereas administration of the same rlL-6 sample failed 
to produce a protective effect when administered at the same 
time as or after Con A  injection.  It should be noted that 
1 Abbreviations used in  this paper: ALT, alanine  aminotransferase;  AST, 
aspartate  aminotransferase. 
the administration of rlL-6 at 6 h after Con A injection in- 
duced significantly enhanced levels of liver injury as assessed 
by an increase in plasma ALT. These results indicate that rlL-6 
can prevent Con A-induced hepatitis, but this cytokine has 
varying effects on the development of hepatitis, depending 
on the stage at which it is present. 
The Effect of rlL-6 Administration on the Production of TNF. 
Finally,  we investigated whether the pretreatment of mice 
Table  2.  Inhibition  of Con A-induced Hepatitis  by Anti-TNF 
but Not Anti-IL-I  or Anti-IL-6  Antibodies 
Percent  inhibition  of 
transaminase  release* 
Treatment  No.  of 
with  Ab*  mice  AST  ALT 
N one  11  -  - 
Anti-TNF  4  82  84 
Anti-IL-1  4  0  0 
Anti-IL-6  3  0  0 
* Various antibodies  against cytokines  were administered  to mice at the 
same time as Con A  (0.3  mg/mouse) injection; anti-TNF mAb, 250 
/~g/mouse;  anti-IL-1  Ab,  250  /zg/mouse;  and  anti-IL-6  mAb,  850 
/zg/mouse. 
* Plasma transaminase  levels were determined 24 h  after  Con A injec- 
tion. Percent inhibition of transaminase release was calculated as follows: 
%  inhibition  =  100  x  [1  -  (transaminase  units  in  Ab-treated 
mice)/(transaminase  units in untreated mice)]. 
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in vivo, but that this modulatory effect is only partial, given 
that  it almost completely protects against  hepatitis. 
Figure 6.  Protective effect of IL-6 administration on the development 
of Con A-induced hepatitis.  Various doses (indicated) of rlL-6 were ad- 
ministrated  to BALB/c mice (five mice per group) 6 h before Con A (0.3 
mg/mouse) injection.  Plasma ALT levels of normal untreated mice were 
41  _+2. 
with rlL-6 influences the production of TNF by Con A in- 
jection, rlL-6 was administered once (at 6 h) or four times 
(at 26,  22,  6,  and 1 h) before Con A  injection (Fig.  8).  A 
single injection ofrlL-6 significantly reduced the production 
of TNFs;  a 40-50%  reduction was observed in plasma ob- 
tained 1 h after Con A injection. This was also the case with 
the suppression of IL-1 production when determined in plasma 
3 h  after Con A  injection. More profound suppression was 
obtained by four rounds of IL-6 injection. This is in contrast 
to almost complete prevention of transaminase release by a 
single rlL-6 administration. Thus, these results indicate that 
Discussion 
The development of hepatitis  or hepatocellular destruc- 
tion has not been studied extensively at the cellular or mo- 
lecular level mainly because of the lack of experimental systems. 
Thus,  an appropriate animal model was required for inves- 
tigating the pathophysiology of immunologically mediated 
hepatic disorders  such as  autoimmune hepatitis,  as well as 
for establishing an attempt to prevent and/or protect from 
the diseases. 
A  new hepatitis model was recently developed in which 
a single injection of Con A resulted in liver injury (12). Using 
this model, the present study investigated the molecular mech- 
anisms (endogenous mediators) underlying the development 
of and protection from hepatitis.  The results demonstrated 
that (a) Con A-induced hepatitis is T  cell activation depen- 
dent  as  massive  infiltration  of lymphoid  cells,  including 
CD4 § T  cells, was detected at the site of injury and FK506- 
pretreated or nude mice failed to develop disease; (b) in addition 
Figure 7.  rlL-6-induced protection depends on its administration  be- 
fore Con A injection, rlL-6 (20 #g/mouse) was administered to BALB/c 
mice (five mice per group) at various hours (indicated) before or after Con 
A (0.3 rag/mouse) injection (time 0). Negative and positive controls rep- 
resent untreated normal mice and mice given Con A injection without 
IL-6 treatment, respectively. Plasma was obtained 24 h after Con A injec- 
tion. (*)p <0.05 vs. positive control; (* *)/~ <0.01 vs. positive control. 
Figure 8.  Effects  of rlL-6 administration  on the production  of TNFs 
and IL-1 by Con A injection,  rib6 (20/zg/mouse) was administered to 
BALB/c mice (more than four mice per group) once (at 6 h) or four times 
(at 26, 22, 6, and 1 h) before Con A (0.3 rag/mouse) injection.  Plasma 
was obtained at various hours after Con A injection, and assayed for TNF 
and IL-1 activity.  (*)p <0.05  vs. control;  (**)v <0.01  vs. control. 
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inflammatory cytokines (TNFs,  IL-1,  and IL-6)  are over- 
produced soon after Con A injection, and elevated levels de- 
creased sharply at later time points; (c) TNFs have a critical 
role in inducing hepatitis, as passive immunization with anti- 
TNF but not with anti-IL-1 or anti-IL-6 antibody conferred 
protection; and (d) rlL-6 also conferred almost complete pro- 
tection, but only when administered at least 3 h before Con 
A injection. The protective effect of this cytokine is medi- 
ated by various mechanisms including its function as a nega- 
tive modulator for TNF production. 
The pathophysiology  of immunologically  mediated hepatic 
disorders has been investigated to date using models for sys- 
temic endotoxic shock (3, 4, 15) and its related hepatitis (5-10). 
The administration of endotoxin to animals can prompt se- 
vere metabolic and physiological disturbances leading to death 
(3, 4, 16). A common observation in endotoxic shock in ro- 
dents is acute liver failure. It has been established that macro- 
phages or their production of TNF-ol are central in causing 
endotoxic reactions (16-18). D-galactosamine, which impairs 
protein biosynthesis only in the liver (11), sensitizes the liver 
by several orders of magnitude toward subtoxic amounts of 
LPS (6). D-galactosamine/LPS-induced liver injury was also 
demonstrated to be mediated by TNF-o~ (9, 10) and induced 
under conditions in which other organs are not affected. Thus, 
this has represented a hepatitis model induced by endoge- 
nous mediators. Nevertheless,  this model may be prone to 
the limitations inherent to the experimental approach. These 
include  presensitization  with  D-galactosamine  (a  specific 
hepatotoxic agent) as an absolute requirement, and disease 
is induced by macrophages or their products without critical 
involvement of activated T cells as required for autoimmune- 
type liver cell destruction (1). In this context, the hepatitis 
induced by Con A (termed Con A-induced hepatitis) may 
represent a more suitable model for hepatitis whose develop- 
ment is associated with T cell activation and induced without 
involvement of metabolically active/toxic substances. 
The following aspects of the Con A-induced hepatitis model 
should be considered. First, it is obvious that the induction 
of hepatitis is dependent on T  cell activation (12 and this 
study). Generalized T cell activation leads to the patholog- 
ical status termed "T cell-mediated cytokine~related  syndrome." 
Previous studies (19-23)  have revealed that the administra- 
tion of anti-CD3 mAb induces shocklike syndromes through 
the overproduction of T  cell-derived lymphokines. Similar 
phenomena were observed by injection of the superantigen 
staphylococcal  enterotoxin B (24).  Animals suffering from 
this syndrome exhibited acute inflammatory lesions in var- 
ious organs (lung and kidney, in addition to liver). We have 
also performed experiments in which shocklike syndromes 
are induced by injection of anti-CD3 mAb. The increase in 
plasma transaminase levels induced by injection of anti-CD3 
mAb was one order of magnitude lower than that induced 
in the Con A model (our unpublished observation). In con- 
trast to the damage to various organs observed in the anti- 
CD3 mAb model, Con A injection leads to induction of liver- 
selective injury. This selectivity could be ascribed,  in part, 
to the fact that hepatocyte plasma membranes strongly bind 
Con A  (25,  26),  accumulating Con A  in the liver. 
Second, the administration of mitogens such as LPS and 
Con A induce particular types of lymphoid cells to rapidly 
release their products. As aforementioned, TNF has been 
identified as a terminal mediator in LPS shock and D-galac- 
tosamine/LPS-induced hepatitis models (6, 9, 16, 18). This 
appears to hold true for T cell-mediated cytokine syndromes 
(19-24) as analyzed most accurately in a bacterial enterotoxin 
shock model (24). In contrast, an earlier publication (12) on 
the Con A-induced hepatitis model described the possibility 
of minimal TNF involvement from the observations that hep- 
atitis was not protected by anti-TNF antibody. However, we 
detected significantly elevated levels of TNFs rapidly after Con 
A injection, and found that passive immunization with anti- 
TNF mAb, which is capable of neutralizing TNF-ot and "3, 
conferred protection. Our results are in accordance with the 
study by Gilles et al. (27) which demonstrated a direct hepato- 
toxic effect of TNF-oe and its protection by anti-TNF mAb. 
The discrepancy in neutralization by anti-TNF mAb may be 
explained by considering the difference in the doses and/or 
relative affinities of anti-TNF mAb used for neutralization. 
250 #g mAb was the dose given in both the study by Gilles 
et al.  (27) and our study, whereas the dose and source of 
antibody were not described in the report by Tiegs et al. (12). 
Thus, our results indicate that TNFs function as major en- 
dogenous mediators in this model, although it is highly pos- 
sible that other cytokines contribute to the induction and/or 
progression of hepatitis. 
In gram-negative septicemia, TNF is produced by macro- 
phages upon injection of LPS (16, 18). T  cells are known 
to produce TNF-ot and -3 (28, 29), both of which bind the 
same receptor (30, 31) and have common effects on a variety 
of target cells (30, 31). Anti-TNF antibody used in our ELISA 
primarily detects TNF-c~ but also cross-reacts with TNF-3. 
mRNA analysis by PCR revealed that both TNF-c~ and -3 
mRNAs are expressed in the liver and spleen (our unpub- 
lished observations).  Thus, it is likely that TNF-oe and -3 
are produced after Con A injection. Irrespective of the TNF 
type, it should be noted that the peak levels of TNFs induced 
by Con A injection in the present model are comparable with 
those induced by LPS injection in the LPS/D-galactosamine 
model. However,  the induction of hepatitis (massive trans- 
aminase release) in these two models differs in the require- 
ment for the treatment of liver cells with D-galactosamine. 
Due to the fact that Con A is selectively accumulated in the 
liver,  Con A  might be visualized  as stimulating the liver 
microenvironment to efficiently induce TNF-c~ and -3-medi- 
ated hepatocellular damage. These TNFs are produced as a 
result of cooperation between responding T ceils and acces- 
sory macrophages (Kupffer cells). 
The third aspect is concerned with the protective effect 
of IL-6 on the development of Con A-induced hepatitis. IL-6 
has been demonstrated to possess pleiotropic biological ac- 
tivities (32, 33). High circulating levels of this cytokine are 
observed in human infectious disease (15, 34), as well as ex- 
perimental endotoxin shock models (35). The biological ac- 
1535  Mizuhara  et al. tivities of IL-6 in acute inflammatory responses have not yet 
been completely uncovered.  IL-6  negatively regulates the 
production of TNFs (36, 37), whereas TNF functions con- 
versely as a positive modulator of IL-6 production (15, 38). 
Regarding the mechanisms by which IL-6 protects from hep- 
atitis, our results suggest the existence of multiple aspects. 
One such aspect is the reduction of TNF production as has 
been reported in other studies (36,  39).  However, a single 
IL-6 injection conferred complete protection against hepa- 
titis whereas TNF production was inhibited by at most 50%. 
Therefore, it is conceivable that IL-6 exerts its protective effect 
through additional mechanisms. IL-6 is a major inducer of 
the acute phase response, mediating the synthesis and release 
of acute  phase  proteins  such  as  C-reactive  protein,  oe2- 
macroglobulin and oel-proteinase inhibitor (40). Furthermore, 
because TNF cytotoxicity may be partly dependent on pro- 
tease activity (41), IL-6-induced production ofprotease (pro- 
teinase) inhibitors by the liver could theoretically contribute 
to moderating TNF cytotoxicity. Thus, IL-6 has the poten- 
tial to reduce the total inflammatory burden mediated by TNF. 
It is important to note that the beneficial effect of IL-6 
administration was observed only when this cytokine was 
given before disease induction. The administration of IL-6 
after Con A injection induced significantly enhanced trans- 
aminase release. The following possibilities may be raised to 
explain the opposing effects of IL-6 on disease severity, de- 
pending on the relative times of administration. It is known 
that in addition to negative regulation of TNF production, 
IL-6 increases the level of TNF-o~ receptor (TNFR) expres- 
sion (42-44) on various types of cells including hepatocytes 
(43).  Because TNF is produced early (only 1 h) after Con 
A injection, IL-6 given 3-6 h after the injection may func- 
tion to enhance the expression of TNFRs  on hepatocytes 
without inhibiting the TNF production. Therefore, it is con- 
ceivable that the already released TNF reacts more effectively 
with hepatocytes expressing increased levels of TNFRs, re- 
sulting in more potent cytotoxic effects on hepatocytes. Al- 
though not mutually exclusive, it is also possible that treat- 
ment with IL-6 may stimulate the generation of some cytotoxic 
mediators. In fact, IL-6 was demonstrated to stimulate the 
release of TNF-oe/lymphotoxin by once activated lymphoid 
cells (42). Thus, IL-6 enhancement of TNF cytotoxicity may 
involve more than the upregulation of TNFRs (44). Irrespec- 
tive of the mechanism(s) underlying IL-6 enhancement, it 
is likely that each pathway is upregulated by a large amount 
of IL-6 endogenously produced after Con A injection. Thus, 
further  studies  will  be  required  to  investigate  how  IL-6 
influences the production/release of various cytokines and the 
expression of TNFRs on hepatocytes, and consequently, en- 
hances the progress of inflammatory lesions when given after 
Con A  injection. 
Our results illustrate that TNF has a critical role in in- 
ducing T cell-mediated hepatitis and that the development 
of disease is completely prevented by IL-6 through poten- 
tiaUy multiple pathways. Thus, the present experimental system 
could provide a model for investigating the pathophysiology 
of T  cell activation-associated hepatitis in humans such as 
autoimmune hepatitis, as well as for developing therapeutic 
approaches based on the observations obtained in such a model. 
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